Researchers found weak associations between pCR and survival outcomes in trials of neoadjuvant therapy for HER2+ breast cancer.

Responses were graded by fellowship-trained breast radiologists.

An assessment of data from the Climb Every Mountain study sought to determine the predictors for physical decline and loss of ADL/IADL in older patients with breast cancer.

Ultrasound sensitivity and specificity were 98.5 and 90.8 percent among women aged 30 years or older with focal breast complaints.

Researchers report on the feasibility of financial screening of patients at an outpatient breast clinic, and patients’ acceptance of screening.

Increased relative risks noted for current or recent use of oral, injected, implanted, IUD progestogen-only contraceptives.

Alisertib monotherapy has shown activity in postmenopausal patients with endocrine-resistant, HER2-negative, metastatic breast cancer, but it was not able to restore sensitivity to fulvestrant in this patient population.

Researchers sought to determine if decision making regarding managing breast cancer risk differed between women of different races at above average risk.

Further, the choice of cutoff used to define high risk also changes individual-level recommendations.

Younger age, uninsured or Medicaid status, and lower household income were associated with longer times to surgery.